CSL Limited (CSL) said that it had received a second request, from the US Federal Trade Commission ("FTC") regarding its proposed acquisition of Talecris Biotherapeutics. CSL said it would respond to the request expeditiously.
The company said that the FTC had not yet reached a conclusion regarding the proposed acquisition.
"The request for additional information from the FTC is a normal part of the US regulatory review process under the Hart-Scott-Rodino Antitrust Improvements Act of 1976," CSL said.
The proposed takeover announced on August 13, 2008 is worth $3.1 billion.
CSL said the acquisition would add 10% to earnings per share and deliver synergies with about US$220 million ($323.8 million) over three years.
At 1012 AEST shares in CSL were up 89c to $37.54.